| 19411071 |
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941
Junttila, TT,
Fields, C,
Sliwkowski, MX,
Lewis Phillips, GD,
Sampath, D,
Friedman, LS,
Parsons, K,
Akita, RW
|
Cancer Cell |
2009 |
| 18754654 |
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Valenti, M,
Workman, P,
Depledge, P,
Alix, S,
Hancox, TC,
Kugendradas, A,
Baker, SJ,
Box, G,
Chuckowree, IS,
Eccles, SA,
Alderton, WK,
Ultsch, MH,
Pang, J,
Clarke, PA,
Saghir, N,
Patel, S,
Zhyvoloup, A,
Wiesmann, C,
Wan, NC,
Moore, P,
Wallweber, HJ,
Zvelebil, MJ,
Pergl-Wilson, GH,
Raynaud, FI,
Ahmadi, K,
Lensun, L,
Hayes, A,
Salphati, L,
Robson, A,
Olivero, AG,
Shuttleworth, SJ,
Sohal, S,
Friedman, LS,
Folkes, AJ
|
J. Med. Chem. |
2008 |
